Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid for Residual Chronic Subdural Hematoma
NCT04898712Phase 2Unknown
- Sponsor
- Unity Health Toronto
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tranexamic acid in chronic subdural hematoma (CSDH), sponsored by Unity Health Toronto. Status: unknown.
02
Drugs
tranexamic acid
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT04898712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898712.